Update on fibroblast growth factor 23 in chronic kidney disease
Kidney International, 05/24/2012
Clinical Article
Wolf M – Fibroblast growth factor 23 (FGF23) itself has now been shown to mediate ‘off–target,’ direct, end–organ toxicity in the heart, which suggests that elevated FGF23 levels may be a novel mechanism of adverse outcomes in chronic kidney disease (CKD). This report reviews recent advances in FGF23 biology relevant to CKD, the classical effects of FGF23 on mineral homeostasis, and the studies that established FGF23 excess as a biomarker and novel mechanism of cardiovascular disease.
